Biosimilars: Who Saves?
How similar molecules may mean similar cost-sharing for patients
White Paper
Jul 03, 2018
This white paper examines the complex cost-sharing environment of biologic therapies and investigates how potential savings will be distributed among stakeholders. Leveraging our expertise in managed markets and patient access, IQVIA's US Market Access Strategy Consulting group brings the relationships between patients, their insurers, and pharmacy benefit managers (PBMs) to the forefront of the biosimilar savings discussion with the intent to accurately represent how these savings will affect the industry and not simply how sizable the savings will be.
You may also be interested in